Europe Multiple Myeloma Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Multiple Myeloma patients study in a new report ‘Europe Multiple Myeloma Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Multiple Myeloma epidemiology, Multiple Myeloma diagnosed patients, and Multiple Myeloma treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Multiple Myeloma derived from epidemiological analysis, percentage of patients diagnosed with Multiple Myeloma, and percentage of patients treated with a therapy.
The study helps executives estimate Multiple Myeloma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Multiple Myeloma prevalence, Multiple Myeloma diagnosis rate, and Multiple Myeloma treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.